CHOONG ANG VACCINE LABORATORY Logo

CHOONG ANG VACCINE LABORATORY

Develops and manufactures vaccines, pharmaceuticals, and feed additives for animals.

072020 | KO

Overview

Corporate Details

ISIN(s):
KR7072020001
LEI:
Country:
South Korea
Address:
대전광역시 유성구 유성대로 1476-37 (주)중앙백신연구소, 대전광역시

Description

Established in 1968, Choong Ang Vaccine Laboratory (CAVAC) is a company specializing in the research, development, manufacture, and sale of animal health products. The company's portfolio includes a wide range of vaccines designed to prevent diseases in various animal species. These products cater to livestock such as cattle and chickens, as well as companion animals including dogs, cats, and rabbits, and also extend to fish. In addition to its core vaccine business, CAVAC also produces other pharmaceutical products and feed additives for the animal health market. The company is recognized for its long-standing presence and pioneering role in the development of animal vaccines.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-14 00:00
반기보고서 (2025.06)
Korean 770.9 KB
2025-08-04 00:00
영업(잠정)실적(공정공시)
Korean 14.2 KB
2025-05-14 00:00
분기보고서 (2025.03)
Korean 569.5 KB
2025-05-02 00:00
영업(잠정)실적(공정공시)
Korean 14.2 KB
2025-03-28 00:00
자기주식취득결과보고서
Korean 42.2 KB
2025-03-25 00:00
정기주주총회결과
Korean 23.3 KB
2025-03-17 00:00
감사보고서제출
Korean 17.9 KB
2025-03-17 00:00
사업보고서 (2024.12)
Korean 447.2 KB
2025-03-10 00:00
주주총회소집공고
Korean 113.5 KB
2025-03-10 00:00
의결권대리행사권유참고서류
Korean 105.7 KB
2025-02-06 00:00
현금ㆍ현물배당결정
Korean 8.8 KB
2025-02-06 00:00
주주총회소집결의
Korean 11.1 KB
2025-02-06 00:00
주요사항보고서(자기주식취득결정)
Korean 28.7 KB
2025-01-08 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 21.5 KB
2024-12-11 00:00
주주명부폐쇄기간또는기준일설정
Korean 4.5 KB

Automate Your Workflow. Get a real-time feed of all CHOONG ANG VACCINE LABORATORY filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for CHOONG ANG VACCINE LABORATORY

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for CHOONG ANG VACCINE LABORATORY via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.